Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage

Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage

Abstract Background It is not a rare clinical scenario to have patients presenting with coexisting malignant tumor and tuberculosis. Whether it is feasible to conduct programmed death-(ligand) 1 [PD-(L)1] inhibitors to these patients, especially those with active tuberculosis treated with concurrent...

Full description

Bibliographic Details
Main Authors: Shan Su, Mei-Feng Ye, Xiao-Ting Cai, Xue Bai, Zhi-Hao Huang, Si-Cong Ma, Jian-Jun Zou, Yu-Xiang Wen, Li-Juan Wu, Xue-Jun Guo, Xian-Lan Zhang, Wen-Chang Cen, Duo-Hua Su, Hui-Yi Huang, Zhong-Yi Dong
Format: Article
Language:English
Published: BMC 2021-12-01
Series:BMC Medicine
Subjects:
Malignant tumor, Tuberculosis, PD1/PD-L1, Efficacy, Safety
Online Access:https://doi.org/10.1186/s12916-021-02194-z

Internet

https://doi.org/10.1186/s12916-021-02194-z

Similar Items